admin – page 3 – eisai china lnc.-pg电子app

 admin – page 3 – eisai china lnc.-pg电子app

entries by

commitment to environmental protection

· environmental protection in line with eisai’s environmental protection policy, eisai china inc. is making every effort to protect the environment and continuously implements cleaner, energy saving production processes at its suzhou plant. to decrease energy consumption, we have installed high-efficient illumination system, energy-saving lamps and other energy-saving equipment in the plant. taking advantage of advanced […]

company profile

  •eisai china headquarter address: floor 39-40, park place, no. 1601, nanjing west road, jing’an district, shanghai tel: 86-21-2419-2888 fax: 86-21-2419-2891 postal code: 200040   •eisai china holdings ltd. eisai china inc. registered address: no.168, xingpu road, suzhou industrial park, suzhou tel: 86-512-69566776 fax: 86-512-67618640  postal code: 215021   •eisai (liaoning) pharmaceutical co., ltd. […]

president’s message

it has been 32 years since eisai came to china in 1991. it is fair to say that eisai’s relationship with china is long-standing and well-established. prof. hans mueller, vice president of beijing medical college (now peking university health science center) and his wife together with their team visited kawashima plant in 1972 when china […]

about eisai china

eisai’s affiliates in china are wholly-owned by eisai co., ltd., a japanese multinational pharmaceutical company headquartered in tokyo, with strong r&d capabilities. it was founded in1941. since its foundation, the company has actively expanded into overseas markets and now has sales subsidiaries and factories in america, europe and asia. eisai china has been smoothly developing […]

abbvie gk (headquarters: minato-ku, tokyo; president: james feliciano, hereafter “abbvie”) and eisai co., ltd. (headquarters: tokyo; ceo: haruo naito, hereafter “eisai”) today announced an approval of additional indication of humira® (generic name: adalimumab [recombinant], hereafter “humira”), a fully human anti-tnfα monoclonal antibody, for the treatment of pyoderma gangrenosum (hereafter “pg”). humira was granted orphan drug designation for the treatment of pg in 2019. this indication counts for humira’s 12th indication in japan and makes humira the world’s first drug indicated for the treatment of pg.

jyseleca® (filgotinib) for rheumatoid arthritis launches in japan

gilead sciences k.k. (head office: chiyoda-ku, tokyo; president and representative director: luc hermans; “gilead”) and eisai co., ltd. (head office: bunkyo-ku, tokyo, ceo: haruo naito; “eisai”) today announced that jyseleca® (filgotinib maleate 200 mg and 100 mg tablets), a new once-daily, oral, jak (janus kinase) inhibitor that preferentially inhibits jak1, will be launched in japan on november 18 for the treatment of rheumatoid arthritis (ra), with prior regulatory approval by the japanese ministry of health, labour and welfare.